Ulcerative colitis
Conditions
Interventions
Control group:Sulfasalazine
Treatment group:Acupuncture combined with mesalazine
Sponsors
Kunming Municipal Health Commission
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Diagnostic Criteria - Meet the diagnostic criteria for ulcerative colitis established by the Inflammatory Bowel Disease Collaborative Group of the Chinese Medical Association in 2020 - Diagnosis confirmed by colonoscopy with supportive biopsy pathology - Disease activity period: Mayo score of 5-10 2. Disease Characteristics - Lesion extent: left-sided colitis or extensive type - Duration of disease: diagnosed for =3 months - Disease activity: mild to moderate active phase (Mayo score of 5-10) 3. Demographic Characteristics - Age: 18-65 years - Gender: unrestricted - Able to understand and sign the informed consent form 4. Treatment Requirements - Oral mesalazine treatment for =4 weeks with a stable dose for =2 weeks - If corticosteroids are used the dose should be =10 mg/d (prednisone equivalent) and the dose should be stable for =2 weeks - Able to complete 12 weeks of treatment and follow-up as per the protocol requirements
Exclusion criteria
Exclusion criteria: 1. Disease-related - Severe ulcerative colitis (Mayo score > 10) - Coexisting infectious enteritis or other intestinal infections - Presence of intestinal strictures, fistulas, or abscesses - History of gastrointestinal bleeding requiring blood transfusion in the past 3 months - Coexisting primary sclerosing cholangitis 2. Treatment history - Use of biological agents in the past 3 months - Use of immunosuppressants in the past month - Acupuncture treatment in the past 2 weeks - Colonic surgery in the past 6 months 3. Comorbidities - Severe heart, liver, or kidney dysfunction - Active tuberculosis or hepatitis B or C virus infection - History of malignant tumors - Coagulation disorders or current use of anticoagulants - Pregnant or breastfeeding women - Presence of a cardiac pacemaker 4. Other - Participation in other clinical trials - Mental illness or cognitive impairment - Infection or skin lesions at the acupuncture site - Anticipated poor compliance or inability to complete follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 12-week clinical remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events;Improvement of Inflammatory Markers;Clinical response rate;Inflammatory Bowel Disease Questionnaire (IBDQ);Mucosal healing rate; | — |
Countries
China
Contacts
Public ContactChunling Li
Kunming Traditional Chinese Medicine Hospital
Outcome results
None listed